Company ProPhase Labs, Inc.

Equities

PRPH

US74345W1080

Healthcare Facilities & Services

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Ratings for ProPhase Labs, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
4.95 ^USD	-2.17%		-9.01%	+9.51%

Apr. 16	Health Care Ticks Up After UnitedHealth Earnings -- Health Care Roundup	DJ
Apr. 16	ProPhase Labs, Inc. Unveils Project ZenQ-AI	CI

ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.

Number of employees: 113

USD in Million	2022	Weight	2023	Weight	Delta
Diagnostic Services 56.0 %	108	88.3 %	25	56.0 %	-77.06%
Consumer Products 44.0 %	14	11.7 %	20	44.0 %	+36.44%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	123	100.0 %	44	100.0 %	-63.81%

Managers	Title	Age	Since
Ted Karkus CEO	Chief Executive Officer	64	09-06-14
Jed Andrew Latkin COO	Chief Operating Officer	50	Dec. 31
Robert Morse AUD	Comptroller/Controller/Auditor	49	22-06-30

Members of the board	Title	Age	Since
Louis Gleckel BRD	Director/Board Member	68	09-05-31
Ted Karkus CEO	Chief Executive Officer	64	09-06-14
Jason Barr BRD	Director/Board Member	44	15-05-31
Warren Hirsch BRD	Director/Board Member	66	19-05-21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,986,176	14,065,207 ( 38.03 %)	18,940,967 ( 51.21 %)	38.03 %

Name	Equities	%	Valuation
Ted Karkus 19.86 %	3,583,750	19.86 %	23 M $
Vanguard Global Advisers LLC 3.377 %	609,347	3.377 %	4 M $
Louis Gleckel 1.518 %	273,840	1.518 %	2 M $
Renaissance Technologies LLC 1.362 %	245,710	1.362 %	2 M $
HighTower Advisors LLC 0.9594 %	173,124	0.9594 %	1 M $
Geode Capital Management LLC 0.7615 %	137,409	0.7615 %	889 036 $
Monica Brady 0.5068 %	91,450	0.5068 %	591 682 $
Perritt Capital Management, Inc. 0.4760 %	85,900	0.4760 %	555 773 $
BlackRock Institutional Trust Co. NA 0.3242 %	58,508	0.3242 %	378 547 $
SVB Wealth LLC 0.2641 %	47,665	0.2641 %	308 393 $

Name	Equities	%	Valuation
LANTERN PHARMA INC. 5.88%	631,195	5.88%	5,554,516 $

ProPhase Labs, Inc.

711 Stewart Avenue Suite 200

11530, Garden City

http://www.prophaselabs.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Medical & Diagnostic Laboratories

	1st Jan change	Capi.
PROPHASE LABS, INC.	+9.51%	89.32M
SONIC HEALTHCARE LIMITED	-17.89%	8.36B
RADNET, INC.	+40.49%	3.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-32.64%	2.73B
SYNLAB AG	-7.88%	2.47B
DR. LAL PATHLABS LIMITED	-7.95%	2.32B
NEOGENOMICS, INC.	-14.40%	1.77B
FLEURY S.A.	-18.74%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.19%	1.22B
METROPOLIS HEALTHCARE LIMITED	+5.57%	1.09B

Medical & Diagnostic Laboratories